Induction of therapeutic levels of HbF in genome‐edited primary β039‐thalassaemia haematopoietic stem and progenitor cells
Authors:
- Maura MingoiaMMMaura Mingoia
- Cristian A. CariaCCCristian A. Caria
- Lin YeLYLin Ye
- Isadora AsunisIAIsadora Asunis
- M. Franca MarongiuMMM. Franca Marongiu
- Laura ManunzaLMLaura Manunza
- M. Carla SollainoMSM. Carla Sollaino
- Jiaming WangJWJiaming Wang
- Annalisa CabrioluACAnnalisa Cabriolu
- Francesco CuccaFCFrancesco Cucca
- 20 November 2020
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 192 (2) , 395-404
Abstract
Summary: Hereditary persistence of fetal haemoglobin (HPFH) is the major modifier of the clinical severity of β‐thalassaemia. The homozygous mutation c.‐196 C>T in the Aγ‐globin (HBG1) promoter, which causes Sardinian δβ0‐thalassaemia, is able to completely rescue the β‐major thalassaemia phenotype caused by the β039‐thalassaemia mutation, ensuring high levels of fetal haemoglobin synthesis during adulthood. Here, we describe a CRISPR/Cas9 genome‐editing approach, combined with the non‐homologous end joining (NHEJ) pathway repair, aimed at reproducing the effects of this naturally occurring HPFH mutation in both HBG promoters. After selecting the most efficient guide RNA in K562 cells, we edited the HBG promoters in human umbilical cord blood‐derived erythroid progenitor 2 cells (HUDEP‐2) and in haematopoietic stem and progenitor cells (HSPCs) from β0‐thalassaemia patients to assess the therapeutic potential of HbF induction. Our results indicate that small deletions targeting the −196‐promoter region restore high levels of fetal haemoglobin (HbF) synthesis in all cell types tested. In pools of HSPCs derived from homozygous β039‐thalassaemia patients, a 20% editing determined a parallel 20% increase of HbF compared to unedited pools. These results suggest that editing the region of HBG promoters around the −196 position has the potential to induce therapeutic levels of HbF in patients with most types of β‐thalassaemia irrespective of the β‐globin gene (HBB) mutations.Keywords
Funding Information
- Regione Autonoma della Sardegna
This publication has 46 references indexed in Scilit:
- Establishment of Immortalized Human Erythroid Progenitor Cell Lines Able to Produce Enucleated Red Blood CellsPLOS ONE, 2013
- Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobinBritish Journal of Haematology, 2011
- β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolismBlood, 2011
- Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfectionJournal of Virological Methods, 2009
- Ineffective erythropoiesis and thalassemiasCurrent Opinion in Hematology, 2009
- Optimal HLA matching in hematopoietic cell transplantationCurrent Opinion in Immunology, 2008
- Pathophysiology of β Thalassemia—A Guide to Molecular TherapiesHematology-American Society Hematology Education Program, 2005
- Genotype-phenotype correlations in β-thalassemiasBlood Reviews, 1994
- Hb F in sickle cell anemiaCellular and Molecular Life Sciences, 1993
- Delta beta (F)-thalassaemia in Sardinia.Journal of Medical Genetics, 1982